glp-1 and parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders Are we measuring the wrong

Berrocal-Zaragoza MI, Murphy MM, Ceruelo S, Quadros EV, Sequeira JM, Fernandez-Ballart JD

Pediatric Patients Dapagliflozin The pharmacokinetics and pharmacodynamics (glucosuria) of dapagliflozin in pediatric patients aged 10 to 17 years with type 2 diabetes mellitus were similar to those observed in adult patients with same renal function

Kyowa Hakko Bio pays close attention to further clinical research and development efforts for improving the stability and bioavailability of glutathione for later use in drug and nutraceutical formulations

If approved, self-pay pricing would start at $149 for the lowest dose, going up to $399 for higher doses